
    insufficient funding
  
['non-small cell lung cancer', 'non-small-cell lung carcinoma', 'lung cancer', 'nsclc']
['theophylline']

        Inclusion Criteria:

          -  Histologically confirmed NSCLC (squamous, adeno-, large cell anaplastic,
             bronchoalveolar, and non-small cell carcinoma NOS): stage IIIB with malignant pleural
             effusion, stage IV, or recurrent disease.

          -  At least one site of measurable disease.

          -  Brain metastasis if present and treated must be stable by CT scan or MRI for at least
             4 weeks after treatment.

          -  Patient must have received and failed at least one line of palliative therapy
             (chemotherapy or biological therapy)

          -  Age >= 18 years.

          -  ECOG performance status 0-2.

          -  Life expectancy >= 3 months.

          -  Laboratory parameters

               -  Hemoglobin levels >= 10.0 (transfusions allowed if necessary).

               -  ANC >= 1,500.

               -  Platelets >= 100k.

               -  Creatinine clearance >= 50 ml/min.

               -  Total and direct bilirubin: < 3.0 x upper institution limit for normal.

               -  Liver function tests: AST, ALT, and AlkP < 3.0 x upper institution limit for
                  normal.

               -  Signed informed consent.

        Exclusion Criteria:

          -  Active or symptomatic cardiac disease such as congestive heart failure, angina
             pectoris or recent myocardial infarction. Patients with history of these conditions
             who are stable taking cardiac medications will also be excluded.

          -  Pregnant or lactating women (negative test for pregnancy is required of women of
             childbearing potential).

          -  Known HIV infection.

          -  Uncontrolled or untreated brain or spinal cord metastases.

          -  Active infection.

          -  Concomitant steroid or other immunosuppressive therapy.

          -  Other active malignancies present within the past three years, except for basal and/or
             squamous cell carcinoma(s) or in situ cervical cancer.

          -  Meningeal carcinomatosis.

          -  Chemotherapy, radiation therapy, or other anti-tumor therapy during the last three
             weeks.

          -  Immune deficiency syndromes, including the following: rheumatoid arthritis, systemic
             lupus erythematousus, Sjogren's disease, sarcoidosis, vasculitis, polymyositis,
             glomerulonephritis.

          -  Compromised lung function:

               -  FeV1 < 30% of the predicted value, or

               -  DLCO < 30% of the predicted value, or

               -  PCO2 > 45 mmHg.
      